 Former headquarters of Roussel-Uclaf, 35 Boulevard des Invalides, 7th arrondissement of Paris | |
| Company type | Public (Société anonyme) |
|---|---|
| Industry | Pharmaceutical |
| Founded | Paris, France (1911) Institut de Sérothérapie Hémopoïétique ISH (1920) Usines Chimiques des Laboratoires Français UCLAF (1928) Société Française de la Pénicilline SOFRAPEN (1947) (Roussel-Uclaf, S.A. incorporated 1961) |
| Founder | Gaston Roussel |
| Defunct | September 30, 1997[1] |
| Fate | Acquired |
| Successor | Hoechst AG (Hoechst Marion Roussel) |
| Headquarters | Paris, France (1911–1995) Romainville, France (1995–1997)[2] |
Area served | Worldwide |
Key people | Gaston Roussel (CEO, 1911–1947) Jean-Claude Roussel (CEO, 1961–1972) Jacques Machizaud (CEO, 1974–1981) Édouard Sakiz (CEO, 1981–1993) Ernst-Günter Afting (CEO, 1994–1995) Jean-Pierre Godard (CEO, 1995–1997) |
| Products | Hemostyl (erythropoietin, horse serum) Rubiazol (carboxysulfamidochrysoidine) Rythmodan (disopyramide) Decis (deltamethrin) Surgam (tiaprofenic acid) Claforan (cefotaxime sodium) Mifegyne (mifepristone, RU-486) Anandron (nilutamide) |
| Revenue |  US$ 3.01 billion (1996)[3] |
| US$ 340 million(1996)[3] | |
Number of employees | 15,673 worldwide (1992)[4] 8,409 in France (1992)[4] 6,533 in France (1996)[5] |
Roussel Uclaf S.A. was a French pharmaceutical company and one of several predecessor companies of today's Sanofi.
It was the second largest French pharmaceutical company[6] before it was acquired by Hoechst AG of Frankfurt, Germany in 1997, with pharmaceutical operations combined into the Hoechst Marion Roussel (HMR) division in the United States. Roussel Uclaf's agrochemical operations had been transferred to Hoechst Schering AgrEvo GmbH in 1994.
HMR subsequently merged in 1999 with Rhône-Poulenc to form Aventis, which then merged in 2004 with Sanofi-Synthélabo to form Sanofi-Aventis, which was since renamed Sanofi. Hoechst Schering AgrEvo merged in 1999 with Rhône-Poulenc's agrochemical division to form Aventis CropScience, which was acquired by Bayer AG in 2002 and combined with Bayer's agrochemical division to form Bayer CropScience.
- ^ Flallo, Laurent (October 2, 1997). "Hoechst Marion Roussel France touché par une des taxes Aubry". Les Échos. p. 8. Hoechst Marion Roussel France - ex-Roussel Uclaf, which juridically disappeared yesterday...
- ^ Aizicovici, Francine (March 7, 1994). "Le désarroi des salariés". Le Monde. headquarters moved to Romainville in April 1995 after 40 years at 35 Boulevard des Invalides, Paris.
- ^ a b "Roussel UCLAF: profits en hausse de 11%". l'Humanité. February 18, 1997.
"Hoechst AG: Roussel Uclaf unit posts net profit increase of 90%". The Wall Street Journal. February 18, 1997. p. A6. 1996: $3.01 billion sales, $339.5 million net profit - ^ a b "Country focus: French chemicals: an industry review". Chemical Week. May 5, 1993. p. S14.
Roussel Uclaf
Sales 1992: F14.8 billion (3.5%). Profit before tax 1992: F1.439 billion (43%). Investment in assets 1992: F930 million (11.8%). Acquisitions in 1992: F452 million. Employees: 15,673; 8,409 of whom are in France. Principal products: Pharmaceuticals (57% of sales), agroveterinary products (23%), bulk pharmaceuticals (13%) and OTC and cosmetics (4%). Roussel Uclaf is owned 65% by Hoechst and 35% by Rhone-Poulenc, which might soon sell its stake to Hoechst. Headquarters: Paris. - ^ Lemaître, Frédéric (December 3, 1996). "Roussel-Uclaf adopte les 35 heures de travail hebdomadaires sans perte de salaire". Le Monde. 6,533 employees in France
- ^ "Roussel Uclaf disappears, giving way to Hoechst Marion Russell". Chemical Business NewsBase. Cambridge: Royal Society of Chemistry. October 14, 1997. 2nd largest pharmaceutical company (after Rhône-Poulenc and ahead of Sanofi)